The FDA has expanded the use of bevacizumab (Avastin) for treatment resistant metastatic colorectal cancer. Results from a clinical trial demonstrated that the drug improved overall survival by 19% compared to patients who received chemotherapy alone. It also improved progression-free survival by 32%. What other conditions is Avastin indicated for?
For more information, please visit San Francisco Business Times.